Direkt zum Inhalt
Merck
  • The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy.

The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy.

Epileptic disorders : international epilepsy journal with videotape (2011-03-12)
Milena Djuric, Ruzica Kravljanac, Gordana Kovacevic, Jelena Martic
ZUSAMMENFASSUNG

The syndrome of malignant migrating partial seizures in infancy is a devastating, age-specific, epileptic encephalopathy, which still presents an aetiological, pathophysiological and therapeutic problem. In this study, we present two patients who were diagnosed with the disease, based on electroclinical symptoms. The patients were treated with a combination of sodium bromide, stiripentol and levetiracetam. The first patient unequivocally responded, following a course of ineffective conventional drugs, and the second, who was diagnosed and treated immediately, showed a more significant therapeutic response. Antiepileptic drugs, previously reported to be beneficial in case reports, when given concomitantly, may substantially reduce the number and severity of seizures, without influence on psychomotor development. [Published with video sequences].

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Natriumbromid, ACS reagent, ≥99.0%
Sigma-Aldrich
Natriumbromid, ReagentPlus®, ≥99%
Sigma-Aldrich
Natriumbromid, ≥99.99% trace metals basis
Sigma-Aldrich
Natriumbromid, BioUltra, ≥99.0% (AT)
Sigma-Aldrich
Stiripentol, ≥98% (HPLC)
Sigma-Aldrich
Natriumbromid, BioXtra, ≥99.0%
Supelco
Dichte-Standard 1.251 kg/m3, H&D Fitzgerald Ltd. Quality